Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

(2017) Kevin Bielamowicz et al.   NEURO-ONCOLOGY

CD70, a novel target of CAR T-cell therapy for gliomas

(2017) Linchun Jin et al.   NEURO-ONCOLOGY

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma

(2017) Khun Visith Keu et al.   Science Translational Medicine

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains

(2016) S. Shiina et al.   Cancer Immunology Research

Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity

(2015) Akemi Kosaka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

(2015) Sabrina Genßler et al.   OncoImmunology

Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57

(2015) Xuekai Zhu et al.   Oncotarget

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

(2015) Jianfeng Han et al.   Scientific Reports

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

(2014) Rachel E Beard et al.   Journal for ImmunoTherapy of Cancer

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

(2013) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

(2013) C. Geldres et al.   CLINICAL CANCER RESEARCH

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

(2013) Bryan D. Choi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma

(2013) Chan-Juan Shen et al.   Journal of Hematology & Oncology

Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

(2013) Meenakshi Hegde et al.   MOLECULAR THERAPY

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

(2012) Kevin KH Chow et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Imaging Immune Response In vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme

(2008) J. Lazovic et al.   CLINICAL CANCER RESEARCH